7P - Frequency of ALK gene rearrangement in Saudi lung cancer

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Cancer Aetiology, Epidemiology, Prevention
Lung and other Thoracic Tumours
Pathology/Molecular Biology
Presenter Fouad Al Dayel
Citation Annals of Oncology (2015) 26 (suppl_1): 1-5. 10.1093/annonc/mdv043
Authors F.H. Al Dayel1, H. Al Husaini2, S. Mohammed1, A. Tulbah1, K. Al Kuraya3
  • 1Pathology And Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, 11211 - Riyadh/SA
  • 2Oncology Center, King Faisal Specialist Hospital and Research Centre, 11211 - Riyadh/SA
  • 3Research Centre, King Faisal Specialist Hospital and Research Centre, 11211 - Riyadh/SA



Lung carcinoma represents 2.6% of cancer seen at King Faisal Specialist Hospital and Research Centre (KFSH&RC) and 4.5% of cancers in Saudi Arabia as per Saudi Cancer Registry. EML4-ALK re-arrangements are found to play an oncogenic driver role in lung adenocarcinoma tumor genesis in 3-6% of cases. ALK gene rearrangement testing can identify patients with adenocarcinoma who are sensitive to ALK kinase inhibitors. However, no data are available on the prevalence of ALK rearrangements changes in Middle Eastern population. Therefore, we carried out this study to evaluate the prevalence of ALK gene rearrangements in lung adenocarcinoma of Saudi patients.


ALK gene rearrangements were studied using fluorescence in situ hybridization (FISH) on 97 adenocarcinoma samples utilizing tissue microarray format. ALK gene rearrangements tested using break-apart probes from Vysis (Abott Molecular, Il, USA).


Ninety seven (97) lung adenocarcinoma cases were evaluated. Three (3) cases exhibited ALK gene rearrangement (3%). Two (2) of these cases were metastatic lung adenocarcinoma, one was a 55 year old male (non-smoker) and the other one was 35 years old (smoker). The third case was 21 year old female (non-smoker) with incidental lung tumor that was staged after lobectomy as T1N2M0. Two (2) cases were moderately differentiated adenocarcinoma and the third one was solid variant of adenocarcinoma. None of our cases showed signet cells or abundant intracellular mucin.


The findings of this retrospective study show that the incidence of ALK gene rearrangements positive adenocarcinoma in Saudi patients is 3%. This is similar to the published data. No characteristic adenocarcinoma subtypes were seen in these 3 cases.


All authors have declared no conflicts of interest.